US3060165A - Preparation of toxic ricin - Google Patents
Preparation of toxic ricin Download PDFInfo
- Publication number
- US3060165A US3060165A US3060165DA US3060165A US 3060165 A US3060165 A US 3060165A US 3060165D A US3060165D A US 3060165DA US 3060165 A US3060165 A US 3060165A
- Authority
- US
- United States
- Prior art keywords
- ricin
- toxic
- solution
- precipitation
- cake
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010039491 Ricin Proteins 0.000 title claims description 46
- 230000002588 toxic Effects 0.000 title claims description 16
- 231100000331 toxic Toxicity 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002244 precipitate Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000005188 flotation Methods 0.000 claims description 8
- 230000001376 precipitating Effects 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
- 238000001556 precipitation Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- 238000000034 method Methods 0.000 description 20
- 238000000605 extraction Methods 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- 239000002245 particle Substances 0.000 description 18
- 235000012970 cakes Nutrition 0.000 description 16
- 230000003000 nontoxic Effects 0.000 description 16
- 231100000252 nontoxic Toxicity 0.000 description 16
- 239000002002 slurry Substances 0.000 description 14
- 239000012065 filter cake Substances 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000001784 detoxification Methods 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 240000000528 Ricinus communis Species 0.000 description 8
- 235000004443 Ricinus communis Nutrition 0.000 description 8
- 238000000227 grinding Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 125000006414 CCl Chemical group ClC* 0.000 description 6
- 231100000765 Toxin Toxicity 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000614 Poison Toxicity 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000000498 ball milling Methods 0.000 description 4
- 238000007664 blowing Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 235000003276 Apios tuberosa Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002456 HOTAIR Polymers 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 240000005158 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000170226 Voandzeia subterranea Species 0.000 description 2
- 235000013030 Voandzeia subterranea Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 235000007924 ground bean Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000003621 hammer milling Methods 0.000 description 2
- 231100000086 high toxicity Toxicity 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000002110 toxicologic Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/14—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from leguminous or other vegetable seeds; from press-cake or oil-bearing seeds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
Definitions
- This invention relates to the method of preparing toxic llClIl.
- Ricin is a protoplasmic poison prepared from castor beans after the extraction of castor oil therefrom. It is most effective as a poison when injected intravenously or inhaled, the latter requiring extreme comminution and small particle size to be effective. It is believed that the toxic action is catalytic rather than stoichiometric which probably accounts for the high toxicity of the agent.
- ricin Because of its relative instability, ricin must be handled with extreme care. In neutral aqueous solution it is stable only up to 60-75 C., and in solid form up to 100110 0, although for short exposures, temperatures up to 130 may be tolerated. It is sensitive to acids, alkalis and halogen and may also be inactivated by mechanical working such as grinding or pulverizing. These factors are of great importance in developing a satisfactory method for preparing the material.
- the castor beans are first ground and pressed to remove most of the oil.
- the pressed cake still retains about 15% oil and this may be removed by means of solvents which will extract an additional 150 pounds of oil per ton of beans and reduce the oil retained in the cake to a little over 1%.
- solvent extraction it is important to prevent detoxification of the protein during the solvent removal step. If residual solvent is removed from the ground beans by blowing with steam, considerable detoxification results. Blowing with nitrogen efiectively prevents detoxification but is expensive when carried out on a large scale.
- the pressed cake or pomace is extracted by agitating with water at a pH of 3.8101 at 25 C. which removes substantially all of the toxic protein.
- the extraction process is operative within a pH range of about 3 to 4.5 although the preferred range is about 3.5 to 4.,
- the optimum operating point is a pH of 3.8-1.1, as indicated above.
- a careful pH control is essential in order that as much non-toxic protein as possible may be eliminated and also that the filtration rate may be held at a satisfactory value.
- Either HCl or H 80 may be used to get the desired pH for the extraction water, but H 50 is preferred due to its lower corrosion rate and ease of handling in concentrated form.
- the acid should be used in reasonably dilute form to prevent undue local concentrations during its addition. A 5% concentration is satisfactory.
- the slurry is filtered using either a conventional recessed plate filter or a continuous string discharge vacuum filter. With the latter about 7% of filter aid, based on meal weight, was found necessary for satisfactory filtration.
- the filtrate from the water extraction step which contains the ricin, was treated with a 16.7% solution of Na SO to precipitate the protein.
- This solution is com- "ice posed of 20 pounds of salt in 100 pounds of water and the amount used was such that the salt content equalled 20% of the filtrate weight.
- This amount and concentration of salt solution was about optimum considering the factors of cost and toxin recovery. Somewhat higher concentrations and larger amounts of solution can be used, however.
- the precipitation process is not limited to the use of Na SO since a saturated solution of NaCl can be used successfully, but Na SO solution gives better nitrogen fractionation, more rapid precipitation, and can be operated under wider pH limits. It is desirable to raise the pH to about 7-8 before precipitation as this gives better ecovery and greater non-toxic nitrogen removal.
- the pH was raised to this value by using NaOH or Na CO the latter being preferred.
- the base used was quite dilute in order to prevent detoxification due to high local concentrations in the solution. A 5% solution of NaOH was used, whereas with Na CO a 12% solution was preferred. In general, this higher pH during precipitation gave a greater non-toxic nitrogen fractionation and at the same time maintained the toxin loss at less than 2%.
- the slurry was filtered using from 1 to 4% filter aid, based on slurry weight, for satisfactory filtration; the amount of filter aid needed being dependent on the type of press used. Washing the filter cake with Na SO solution removed additional non-toxic nitrogen which is desirable. In this washing step a 16.7% solution of Na SO was again used. This washing step removed an additional 15% of non-toxic nitrogen from the cake.
- the filter cake which contains the ricin in combination with the Na SO may be dried and slurried with CCL, to separate the ricin by flotation. Separation of the ricin after a single precipitation and washing step is possible, but it is preferred to carry the process through an additional extraction and precipitation step. This is accomplished by slurrying the filter cake in three times its weight of water and the pH of the slurry is again brought to 3.8:.1 by means of 5% H The slurry is filtered and a second precipitation is brought about by adding Na SO solution. Although pH control here is not wholly essential it is advantageous to bring the pH to approximate neutrality by adding 12% Na CO A precipitation time of 45 minutes was necessary to obtain complete removal of the toxin.
- the ricin-Na SO precipitate was dried at about 50 to 60 C. on a hot air tray dryer.
- the dried product was ground to pass a 40 mesh screen and agitated with 5 times its weight of CCl.;, which served the separate the ricin from the Na SO by flotation. After settling, the ricin was skimmed off the top. This reduced the Na SO content of the mixture from a previous 40 to 50% down to 15 to 18%. About 1 to 2% of nitrogen remained in the Na SO salt which could then be used for subsequent precipitations.
- Spray drying proved to be an even better method of securing a reasonably small particle size. Best results Were achieved by using a solution having about 20% solids, an inlet temperature of 150 C. and an atomizing air pressure of 150 to 180 psi. The particle size secured was 6 to 8 mu.
- the best means of securing a small particle size was by air grinding. This was carried out in an apparatus having a chamber with conical top and bottom. The material to be ground has been fed into this chamber and is withdrawn from the bottom and forced back into the center of the chamber tangentially through a venturi. Compressed air of about 100 psi. was fed to the venturi to provide the grinding force. The fines are drawn off the top and the large particles settle to the bottom to be recirculated and reground. This process produced particles having a mass median diameter of 2.5 to 3.5 mu.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Processing Of Solid Wastes (AREA)
Description
Oct. 23, 1962 H. L. CRAIG ETAL 3,060,165
PREPARATION OF TOXIC RICIN Filed July 3, 1952 LSlurry with waterI pH of 3.8 sou using 5% u so,
LPrecipitate with N 80 pH of 7 using l2% Na,CO,
l Wash filter cake with |6.7% M0 80 I Single extraction Wash solution Extract with wateri pH of 3.8#O.l using H 80 iii Precipitate with Na IpH of 7 using i2% Na ()0 [E'E l Wash filter cake with l6.7% No.80 I
Wash solution Grind cake to 40 mesh Slurry with CCI.
| Settle and skim oft Ricin i Settled M0 reuse I N VEN TORS Harry L. Craig 0. h. A/derks Alsop/l H. 00min Sally h. Die/re 0h affe L. Karel BY 4 14 W ATTORNEY Dry and grind States. ate
This invention relates to the method of preparing toxic llClIl.
Ricin is a protoplasmic poison prepared from castor beans after the extraction of castor oil therefrom. It is most effective as a poison when injected intravenously or inhaled, the latter requiring extreme comminution and small particle size to be effective. It is believed that the toxic action is catalytic rather than stoichiometric which probably accounts for the high toxicity of the agent.
Because of its relative instability, ricin must be handled with extreme care. In neutral aqueous solution it is stable only up to 60-75 C., and in solid form up to 100110 0, although for short exposures, temperatures up to 130 may be tolerated. It is sensitive to acids, alkalis and halogen and may also be inactivated by mechanical working such as grinding or pulverizing. These factors are of great importance in developing a satisfactory method for preparing the material.
Although ricin has been prepared in crystalline condition in the laboratory in small quantities, it becomes necessary, for purposes of toxicological warfare, to prepare relatively large quantities in a high state of purity. This necessitates that as much as possible of the non-toxic material present be removed in the process.
In preparing the protein material, the castor beans are first ground and pressed to remove most of the oil. The pressed cake still retains about 15% oil and this may be removed by means of solvents which will extract an additional 150 pounds of oil per ton of beans and reduce the oil retained in the cake to a little over 1%. In the event that the expressing step is supplemented by solvent extraction, it is important to prevent detoxification of the protein during the solvent removal step. If residual solvent is removed from the ground beans by blowing with steam, considerable detoxification results. Blowing with nitrogen efiectively prevents detoxification but is expensive when carried out on a large scale.
After the oil has been removed, the pressed cake or pomace is extracted by agitating with water at a pH of 3.8101 at 25 C. which removes substantially all of the toxic protein. The extraction process is operative within a pH range of about 3 to 4.5 although the preferred range is about 3.5 to 4., The optimum operating point is a pH of 3.8-1.1, as indicated above. A careful pH control is essential in order that as much non-toxic protein as possible may be eliminated and also that the filtration rate may be held at a satisfactory value. Either HCl or H 80 may be used to get the desired pH for the extraction water, but H 50 is preferred due to its lower corrosion rate and ease of handling in concentrated form. The acid should be used in reasonably dilute form to prevent undue local concentrations during its addition. A 5% concentration is satisfactory.
Following the extraction, the slurry is filtered using either a conventional recessed plate filter or a continuous string discharge vacuum filter. With the latter about 7% of filter aid, based on meal weight, was found necessary for satisfactory filtration.
The filtrate from the water extraction step, which contains the ricin, was treated with a 16.7% solution of Na SO to precipitate the protein. This solution is com- "ice posed of 20 pounds of salt in 100 pounds of water and the amount used was such that the salt content equalled 20% of the filtrate weight. This amount and concentration of salt solution was about optimum considering the factors of cost and toxin recovery. Somewhat higher concentrations and larger amounts of solution can be used, however.
The precipitation process is not limited to the use of Na SO since a saturated solution of NaCl can be used successfully, but Na SO solution gives better nitrogen fractionation, more rapid precipitation, and can be operated under wider pH limits. It is desirable to raise the pH to about 7-8 before precipitation as this gives better ecovery and greater non-toxic nitrogen removal. The pH was raised to this value by using NaOH or Na CO the latter being preferred. The base used was quite dilute in order to prevent detoxification due to high local concentrations in the solution. A 5% solution of NaOH was used, whereas with Na CO a 12% solution was preferred. In general, this higher pH during precipitation gave a greater non-toxic nitrogen fractionation and at the same time maintained the toxin loss at less than 2%.
After precipitation, the slurry was filtered using from 1 to 4% filter aid, based on slurry weight, for satisfactory filtration; the amount of filter aid needed being dependent on the type of press used. Washing the filter cake with Na SO solution removed additional non-toxic nitrogen which is desirable. In this washing step a 16.7% solution of Na SO was again used. This washing step removed an additional 15% of non-toxic nitrogen from the cake.
After filtration the filter cake, which contains the ricin in combination with the Na SO may be dried and slurried with CCL, to separate the ricin by flotation. Separation of the ricin after a single precipitation and washing step is possible, but it is preferred to carry the process through an additional extraction and precipitation step. This is accomplished by slurrying the filter cake in three times its weight of water and the pH of the slurry is again brought to 3.8:.1 by means of 5% H The slurry is filtered and a second precipitation is brought about by adding Na SO solution. Although pH control here is not wholly essential it is advantageous to bring the pH to approximate neutrality by adding 12% Na CO A precipitation time of 45 minutes was necessary to obtain complete removal of the toxin. In filtering out the precipitate, no filter aid was used and the filter cake was washed with Na SO solution on the filter whereby an additional amount of nontoxic nitrogen was removed from the cake. This washing was effective only the first time and repeated washings had little effect in removing further non-toxic nitrogen.
The ricin-Na SO precipitate was dried at about 50 to 60 C. on a hot air tray dryer. The dried product was ground to pass a 40 mesh screen and agitated with 5 times its weight of CCl.;, which served the separate the ricin from the Na SO by flotation. After settling, the ricin was skimmed off the top. This reduced the Na SO content of the mixture from a previous 40 to 50% down to 15 to 18%. About 1 to 2% of nitrogen remained in the Na SO salt which could then be used for subsequent precipitations.
The final precipitation produced a particle size of 1-2 mu. On drying the wet cake, however, the ricin cemented together forming larger particles. These could not be broken down to their original size by ordinary grinding methods and since a very fine particle size was necessary in order that the product might be used as a toxic weapon, it was thought desirable to seek some method to prevent the agglomeration or cementing process that took place on drying.
To attempt to affect this result, physical conditions prevailing under the precipitation process were changed.
This included changing the temperature of precipitation and the rate of agitation. Other changes included precipitation with ony partial saturation of Na SO and the use of wetting and seeding agents. None of these expedients produced any significant improvement in particle size.
Ordinary dry ball and hammer milling of the dried ricin produced considerable detoxifiiation perhaps due to the generation of excess heat. The use of CCl slurry plus the use of low temperature and low moisture content of the ricin reduced detoxification during ball milling.
Spray drying proved to be an even better method of securing a reasonably small particle size. Best results Were achieved by using a solution having about 20% solids, an inlet temperature of 150 C. and an atomizing air pressure of 150 to 180 psi. The particle size secured was 6 to 8 mu.
The best means of securing a small particle size was by air grinding. This was carried out in an apparatus having a chamber with conical top and bottom. The material to be ground has been fed into this chamber and is withdrawn from the bottom and forced back into the center of the chamber tangentially through a venturi. Compressed air of about 100 psi. was fed to the venturi to provide the grinding force. The fines are drawn off the top and the large particles settle to the bottom to be recirculated and reground. This process produced particles having a mass median diameter of 2.5 to 3.5 mu.
Numerous variations are possible in the several steps of the process commencing with the water extraction and precipitation which may be a single or multiple step. Although a single extraction step can be used, as indicated before, some process modifications are necessary for its successful operation on a plant scale. Double extraction proved to be quite efiicien-t but additional steps beyond the second extraction step were not found necessary.
The drawing is self-descriptive and shows the various steps of the process described.
We claim:
1. In a method of preparing toxic ricin from castor beans comprising slurrying an expressed castor bean cake with water to remove the water soluble ricin and precipitating the ricin from the filtrate, the further steps which include slurrying the precipitate with CCl and separating the ricin by flotation.
2. A process in accordance with claim 1 in which the precipitate is dried prior to slurrying.
References Cited in the file of this patent J. Gen. Physiol, vol. 32 (1948), pages 25-31.
Claims (1)
1.IN A METHOD OF PREPARING TOXIC RICIN FROM CASTOR BEANS COMPRISING SLURRYING AN EXPRESSED CASTOR BEAN CAKE WITH WATER TO REMOVE THE WATER SOLUBLE RICIN AND PRECIPI-TATING THE RICIN FROM THE FILTRATE, THE FURTHER STEPS WHICH INCLUDE SLURRYING THE PRECIPITATE WITH CC14 AND SEPARATING THE RICIN BY FLOTATION.
Publications (1)
Publication Number | Publication Date |
---|---|
US3060165A true US3060165A (en) | 1962-10-23 |
Family
ID=3451002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US3060165D Expired - Lifetime US3060165A (en) | Preparation of toxic ricin |
Country Status (1)
Country | Link |
---|---|
US (1) | US3060165A (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4459287A (en) * | 1979-11-09 | 1984-07-10 | Eisai Co., Ltd. | Immunopotentiator containing recin |
US4985541A (en) * | 1987-04-10 | 1991-01-15 | Zymogenetics, Inc. | Novel cytotoxic protein |
WO2005052006A2 (en) | 2003-11-25 | 2005-06-09 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
EP2011801A1 (en) | 1999-05-27 | 2009-01-07 | Government of the United States as represented by the Secretary, Department of Health and Human Services | Immunoconjugates having high binding affinity |
WO2009099961A2 (en) | 2008-01-31 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
WO2012015912A1 (en) | 2010-07-30 | 2012-02-02 | Medimmune, Llc | Method for purifying active polypeptides or immunocojugates |
WO2013034660A1 (en) | 2011-09-09 | 2013-03-14 | Medimmune Limited | Anti-siglec-15 antibodies and uses thereof |
WO2013039916A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
WO2013138643A1 (en) | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Soluble engineered monomeric fc |
WO2015069922A2 (en) | 2013-11-06 | 2015-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
WO2016019280A1 (en) | 2014-07-31 | 2016-02-04 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies against epha4 and their use |
WO2016201394A1 (en) | 2015-06-12 | 2016-12-15 | Miltenyi Biotec Technology, Inc. | Method to treat cancer with engineered t-cells |
WO2017062952A1 (en) | 2015-10-09 | 2017-04-13 | Miltenyi Biotec Technology, Inc. | Chimeric antigen receptors and methods of use |
WO2018045325A1 (en) | 2016-09-02 | 2018-03-08 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
WO2018129524A1 (en) | 2017-01-09 | 2018-07-12 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-mesothelin immunotherapy |
WO2018175988A1 (en) | 2017-03-24 | 2018-09-27 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd33 immunotherapy |
WO2019028051A1 (en) | 2017-07-31 | 2019-02-07 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy |
WO2019055842A1 (en) | 2017-09-15 | 2019-03-21 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19 immunotherapy |
WO2019079249A1 (en) | 2017-10-16 | 2019-04-25 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd22 immunotherapy |
EP3494992A1 (en) | 2012-12-20 | 2019-06-12 | Medimmune, LLC | Refolding and purification of moxetumomab pasudotox |
WO2019126464A2 (en) | 2017-12-20 | 2019-06-27 | Lentigen Technology, Inc. | Compositions and methods for treating hiv/aids with immunotherapy |
EP3620470A1 (en) | 2013-10-11 | 2020-03-11 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Tem8 antibodies and their use |
WO2020061498A1 (en) | 2018-09-20 | 2020-03-26 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd123 immunotherapy |
WO2020069184A2 (en) | 2018-09-26 | 2020-04-02 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy |
WO2020113108A1 (en) | 2018-11-30 | 2020-06-04 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd38 immunotherapy |
WO2020181164A1 (en) | 2019-03-06 | 2020-09-10 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with self-driving chimeric antigen receptors |
WO2020243546A1 (en) | 2019-05-30 | 2020-12-03 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-bcma immunotherapy |
WO2021003297A1 (en) | 2019-07-02 | 2021-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind egfrviii and their use |
WO2021262723A1 (en) | 2020-06-22 | 2021-12-30 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy |
WO2022099026A1 (en) | 2020-11-05 | 2022-05-12 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy |
US11590169B1 (en) | 2022-03-02 | 2023-02-28 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD123 immunotherapy |
WO2023168243A1 (en) | 2022-03-02 | 2023-09-07 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd123 immunotherapy |
WO2024026107A2 (en) | 2022-07-28 | 2024-02-01 | Lentigen Technology, Inc. | Chimeric antigen receptor therapies for treating solid tumors |
WO2024044743A1 (en) | 2022-08-26 | 2024-02-29 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy |
-
0
- US US3060165D patent/US3060165A/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
None * |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4459287A (en) * | 1979-11-09 | 1984-07-10 | Eisai Co., Ltd. | Immunopotentiator containing recin |
US4985541A (en) * | 1987-04-10 | 1991-01-15 | Zymogenetics, Inc. | Novel cytotoxic protein |
EP2011801A1 (en) | 1999-05-27 | 2009-01-07 | Government of the United States as represented by the Secretary, Department of Health and Human Services | Immunoconjugates having high binding affinity |
EP2204385A1 (en) | 2003-11-25 | 2010-07-07 | The Government Of U.S.A, As Represented By Secretary, Department of Health and Human Sevices | Pseudomonas exotoxin A mutants and uses thereof |
WO2005052006A2 (en) | 2003-11-25 | 2005-06-09 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
EP2594584A1 (en) | 2008-01-31 | 2013-05-22 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Engineered constant domain molecule of an antibody |
WO2009099961A2 (en) | 2008-01-31 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
WO2012015912A1 (en) | 2010-07-30 | 2012-02-02 | Medimmune, Llc | Method for purifying active polypeptides or immunocojugates |
EP3797847A1 (en) | 2010-07-30 | 2021-03-31 | Medlmmune, LLC | Purified active polypeptides or immunoconjugates |
EP3434346A1 (en) | 2010-07-30 | 2019-01-30 | Medimmune, LLC | Purified active polypeptides or immunoconjugates |
US10556955B2 (en) | 2010-07-30 | 2020-02-11 | Medimmune Limited | Method for purifying active polypeptides or immunoconjugates |
US11136396B2 (en) | 2010-07-30 | 2021-10-05 | Medimmune Limited | Method for purifying active polypeptides or immunoconjugates |
WO2013034660A1 (en) | 2011-09-09 | 2013-03-14 | Medimmune Limited | Anti-siglec-15 antibodies and uses thereof |
WO2013039916A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
WO2013138643A1 (en) | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Soluble engineered monomeric fc |
EP3494992A1 (en) | 2012-12-20 | 2019-06-12 | Medimmune, LLC | Refolding and purification of moxetumomab pasudotox |
EP4269421A2 (en) | 2013-10-11 | 2023-11-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Tem8 antibodies and their use |
EP3620470A1 (en) | 2013-10-11 | 2020-03-11 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Tem8 antibodies and their use |
WO2015069922A2 (en) | 2013-11-06 | 2015-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
WO2016019280A1 (en) | 2014-07-31 | 2016-02-04 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies against epha4 and their use |
EP3473271A1 (en) | 2014-07-31 | 2019-04-24 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Human monoclonal antibodies against epha4 and their use |
US12037404B2 (en) | 2014-07-31 | 2024-07-16 | The Hong Kong University Of Science And Technology | Human monoclonal antibodies against EphA4 and their use |
US10934360B2 (en) | 2014-07-31 | 2021-03-02 | The Hong Kong University Of Science And Technology | Human monoclonal antibodies against EPHA4 and their use |
US10639329B2 (en) | 2015-06-12 | 2020-05-05 | Lentigen Technology, Inc. | Method to treat cancer with engineered T-cells |
WO2016201394A1 (en) | 2015-06-12 | 2016-12-15 | Miltenyi Biotec Technology, Inc. | Method to treat cancer with engineered t-cells |
EP4286511A2 (en) | 2015-06-12 | 2023-12-06 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
EP3845557A1 (en) | 2015-06-12 | 2021-07-07 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
WO2017062952A1 (en) | 2015-10-09 | 2017-04-13 | Miltenyi Biotec Technology, Inc. | Chimeric antigen receptors and methods of use |
EP3660044A1 (en) | 2015-10-09 | 2020-06-03 | Miltenyi Biotec Technology, Inc. | Chimeric antigen receptors and methods of use |
WO2018045325A1 (en) | 2016-09-02 | 2018-03-08 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
WO2021102337A1 (en) | 2016-09-02 | 2021-05-27 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
WO2020061194A2 (en) | 2016-09-02 | 2020-03-26 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
EP4282969A2 (en) | 2016-09-02 | 2023-11-29 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
EP3882265A1 (en) | 2017-01-09 | 2021-09-22 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-mesothelin immunotherapy |
WO2018129524A1 (en) | 2017-01-09 | 2018-07-12 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-mesothelin immunotherapy |
EP4183798A1 (en) | 2017-01-09 | 2023-05-24 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-mesothelin immunotherapy |
WO2018175988A1 (en) | 2017-03-24 | 2018-09-27 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd33 immunotherapy |
WO2019028051A1 (en) | 2017-07-31 | 2019-02-07 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy |
EP4279086A2 (en) | 2017-09-15 | 2023-11-22 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19 immunotherapy |
WO2019055842A1 (en) | 2017-09-15 | 2019-03-21 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19 immunotherapy |
EP4279584A2 (en) | 2017-10-16 | 2023-11-22 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd22 immunotherapy |
WO2019079249A1 (en) | 2017-10-16 | 2019-04-25 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd22 immunotherapy |
WO2019126464A2 (en) | 2017-12-20 | 2019-06-27 | Lentigen Technology, Inc. | Compositions and methods for treating hiv/aids with immunotherapy |
WO2020061498A1 (en) | 2018-09-20 | 2020-03-26 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd123 immunotherapy |
US12037403B2 (en) | 2018-09-20 | 2024-07-16 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD123 immunotherapy |
WO2020069184A2 (en) | 2018-09-26 | 2020-04-02 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy |
WO2020113108A1 (en) | 2018-11-30 | 2020-06-04 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd38 immunotherapy |
WO2020181164A1 (en) | 2019-03-06 | 2020-09-10 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with self-driving chimeric antigen receptors |
US11052112B2 (en) | 2019-05-30 | 2021-07-06 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-BCMA immunotherapy |
WO2020243546A1 (en) | 2019-05-30 | 2020-12-03 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-bcma immunotherapy |
WO2021003297A1 (en) | 2019-07-02 | 2021-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind egfrviii and their use |
WO2021262723A1 (en) | 2020-06-22 | 2021-12-30 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy |
WO2022099026A1 (en) | 2020-11-05 | 2022-05-12 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy |
WO2023168243A1 (en) | 2022-03-02 | 2023-09-07 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd123 immunotherapy |
US11590169B1 (en) | 2022-03-02 | 2023-02-28 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD123 immunotherapy |
WO2024026107A2 (en) | 2022-07-28 | 2024-02-01 | Lentigen Technology, Inc. | Chimeric antigen receptor therapies for treating solid tumors |
WO2024044743A1 (en) | 2022-08-26 | 2024-02-29 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3060165A (en) | Preparation of toxic ricin | |
US5135765A (en) | Process for producing protein-rich product, fibrous product and/or vegetable oil from brewer's spent grain | |
US2881159A (en) | Process for isolating soya protein | |
US4277411A (en) | Extraction of oil from vegetable materials | |
JPS58501207A (en) | Lupine extraction method and equipment | |
WO1999029189A1 (en) | A method for making a reconstituted tobacco sheet using steam exploded tobacco | |
US4100305A (en) | Method of making an improved coffee volatiles concentrate | |
CA1129176A (en) | Process of recovering potassium chloride | |
US4151310A (en) | Soybean protein extract | |
US3408374A (en) | Process for the treatment of vegetable materials | |
JPS5843745A (en) | Extraction of roasted ground coffee | |
US2811411A (en) | Method of processing monazite sand | |
US2044769A (en) | Process for preparing zein | |
US3392028A (en) | Fermentation of tea | |
DE2704017A1 (en) | PROCESS FOR PRODUCING SOLUBLE COFFEE | |
GB2078703A (en) | Producing active silica | |
US4191336A (en) | Process for recovering magnetite from fly ash | |
US4128637A (en) | Process for producing thymosin | |
US3908033A (en) | Preparation of soluble coffee | |
GB2094334A (en) | Extracting oil, protein and flour from fresh coconut meat | |
US2593528A (en) | Mucilaginous materials from flaxseed | |
US3669680A (en) | Peroxide extraction of tea leaf | |
US2275661A (en) | Wax extraction | |
US3809775A (en) | Preparation of coffee | |
Pominski et al. | Production of peanut protein |